Ivan Hyep
Known title: Chief Financial OfficerCIK: 0002034668
Associated companies
Transaction History
| BCAX | ▲ Buy | Option Exercise | 12,500 | $47K | 8/10/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 12,500 | $350K | 8/10/2026 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 12,500 | $47K | 7/8/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 22,757 | $651K | 7/8/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 4,413 | $132K | 7/8/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 830 | $25K | 7/8/2026 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 9,200 | $35K | 5/21/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 9,200 | $188K | 5/21/2026 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 9,200 | $35K | 4/21/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 9,200 | $212K | 4/21/2026 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 9,200 | $35K | 3/23/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 9,200 | $170K | 3/23/2026 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 2,963 | $11K | 3/4/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 2,963 | $54K | 3/4/2026 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 7,318 | $28K | 3/3/2026 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 6,237 | $24K | 3/3/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 13,555 | $247K | 3/3/2026 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 1,882 | $7K | 1/22/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 1,882 | $34K | 1/22/2026 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 9,200 | $35K | 12/22/2025 | View on chart |
| BCAX | ▼ Sell | Open Market | 9,200 | $168K | 12/22/2025 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 17,795 | $67K | 11/24/2025 | View on chart |
| BCAX | ▼ Sell | Open Market | 17,795 | $330K | 11/24/2025 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 605 | $2K | 11/21/2025 | View on chart |
| BCAX | ▼ Sell | Open Market | 605 | $11K | 11/21/2025 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 6,415 | $24K | 10/9/2025 | View on chart |
| BCAX | ▼ Sell | Open Market | 6,415 | $117K | 10/9/2025 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 5,627 | $21K | 10/8/2025 | View on chart |
| BCAX | ▼ Sell | Open Market | 5,627 | $102K | 10/8/2025 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 18,244 | $69K | 10/7/2025 | View on chart |
| BCAX | ▼ Sell | Open Market | 18,244 | $332K | 10/7/2025 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 6,514 | $25K | 10/6/2025 | View on chart |
| BCAX | ▼ Sell | Open Market | 6,514 | $118K | 10/6/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
BCAX flagged as potentially overvalued on book value
A recent analysis suggests Bicara Therapeutics stock may be overvalued when compared to its book value. This valuation concern is notable given that the stock is currently trading near its 52-week low and has an RSI of 30.1, indicating it is in oversold territory. While the average analyst target is $35.50, the wide range of estimates reflects significant uncertainty about the company's future performance.
BCAX flagged as potentially overvalued on book value. A recent analysis suggests Bicara Therapeutics stock may be overvalued when compared to its book value. This valuation concern is notable given that the stock is currently trading near its 52-week low and has an RSI of 30.1, indicating it is in oversold territory. While the average analyst target is $35.50, the wide range of estimates reflects significant uncertainty about the company's future performance.